Table 1.
Clinical data of 17 patients with PTU-induced AAV and 64 patients with primary AAV
|
PTU-induced AAV |
Primary AAV |
|
|---|---|---|
| (n = 17) | (n = 64) | |
| Male/female |
2/15 |
32/32 |
| Age (years) |
30.8 ± 15.2 |
60.48 ± 15.14 |
| Scr (μM) |
|
|
| Mean ± SD |
75.62 ± 40.64 |
339.11 ± 237.71 |
| Range |
38-176.9 |
70-1007 |
| Renal insufficiency at diagnosis |
13 (76.4%) |
48 (75%) |
| ESR (mm/1 hour) |
46.92 ± 38.86 |
70.05 ± 40.14 |
| Skin rash |
5(29.4%) |
7 (10.9%) |
| Arthralgia |
9(52.9%) |
15(23.4%) |
| Muscle pain |
6 (35.3%) |
10 (15.6%) |
| Lung |
6 (35.3%) |
43 (67.2%) |
| ENT |
6 (35.2%) |
27(42.2%) |
| Ophthalmic |
2 (11.8%) |
14(21.9%) |
| Gastrointestinal |
3(17.6%) |
11(17.2%) |
| Nervous system |
1 (5.9%) |
10(15.6%) |
| BVAS |
|
|
| Mean ± SD |
17.1 ± 5.5 |
20.27 ± 5.18 |
| Range | 7-31 | 13-36 |
AAV ANCA-associated vasculitis, BVAS Birmingham Vasculitis Activity Scores, ENT ear, nose, and throat, SD standard deviation.